Athira Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

athira.com

Founded Year

2011

Stage

IPO | IPO

Total Raised

$116.02M

Date of IPO

9/18/2020

Market Cap

0.11B

Stock Price

3.06

About Athira Pharma

Athira Pharma (NASDAQ: ATHA) is a drug development company that strives to improve human health by advancing new therapies for neurodegenerative diseases, like Alzheimer's and Parkinson's. The company's approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.

Athira Pharma Headquarter Location

4000 Mason Road Suite 300

Seattle, Washington, 98195,

United States

206-221-8112

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Athira Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Athira Pharma is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Athira Pharma Patents

Athira Pharma has filed 2 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Neurotrauma
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/1/2017

6/1/2021

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Grant

Application Date

6/1/2017

Grant Date

6/1/2021

Title

Related Topics

Neurotrauma, Rare diseases, Neurological disorders, Amino acids, Autosomal recessive disorders

Status

Grant

Latest Athira Pharma News

4 Analysts Have This to Say About Athira Pharma

Jun 24, 2022

Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: Latest Ratings for ATHA DateFirmActionFromTo Dec 2021Goldman SachsInitiates Coverage OnNeutral Oct 2020JefferiesInitiates Coverage OnBuy Oct 2020JMP SecuritiesInitiates Coverage OnMarket Outperform View More Analyst Ratings for ATHA View the Latest Analyst Ratings read more

Athira Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Athira Pharma Rank

  • When was Athira Pharma founded?

    Athira Pharma was founded in 2011.

  • Where is Athira Pharma's headquarters?

    Athira Pharma's headquarters is located at 4000 Mason Road, Seattle.

  • What is Athira Pharma's latest funding round?

    Athira Pharma's latest funding round is IPO.

  • How much did Athira Pharma raise?

    Athira Pharma raised a total of $116.02M.

  • Who are the investors of Athira Pharma?

    Investors of Athira Pharma include Surveyor Capital, Logos Capital, RTW Investments, Venrock, Highside Capital Management and 23 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.